Amendment and Response

Applicants: Adler et al. Serial No.: 10/091,166 Filed: March 5, 2002

For: NOVEL BETA-DEFENSINS

In the Claims

Please cancel claims 26, 28-29, 37, 38, 40-44, 47, 48 and 49, without prejudice.

Per 37 C.F.R. §1.121, the current status of all the claims in the present application is presented below.

Claim 1 (previously presented): An isolated protein comprising a polypeptide that is at least 95% identical to amino acid residues 23 to 67 of SEQ ID NO:10; wherein the polypeptide has antimicrobial activity.

Claim 2 (previously presented): The isolated protein of claim 1 wherein the amino acid percent identity is determined using a FASTA program with ktup=1, gap opening penalty=10, gap extension penalty=1, and substitution matrix=BLOSUM62, with other parameters set as default.

Claim 3 (previously presented): The isolated protein of claim 1 wherein the polypeptide comprises amino acid residues 23 to 67 of SEQ ID NO:10.

Claim 4 (previously presented): An isolated polypeptide selected from the group consisting of:

- a) amino acid residue 30 to amino acid residue 63 of SEQ ID NO:2;
- b) amino acid residue 31 to amino acid residue 63 of SEQ ID NO:2;
- c) amino acid residue 30 to amino acid residue 64 of SEQ ID NO:2;
- d) amino acid residue 31 to amino acid residue 64 of SEQ ID NO:2; and
- e) amino acid residue 23 to amino acid residue 67 of SEQ ID NO:10.

Claim 5 (previously presented): A pharmaceutical composition comprising a polypeptide selected from the group consisting of:

- a) a protein according to claim 1;
- b) amino acid residue 30 to amino acid residue 63 of SEQ ID NO:2;
- c) amino acid residue 31 to amino acid residue 63 of SEQ ID NO:2;

Applicants: Adler et al. Serial No.: 10/091,166 Filed: March 5, 2002

For: NOVEL BETA-DEFENSINS

- d) amino acid residue 30 to amino acid residue 64 of SEQ ID NO:2;
- e) amino acid residue 31 to amino acid residue 64 of SEQ ID NO:2; and
- f) amino acid residue 23 to amino acid residue 67 of SEQ ID NO:10; in combination with a pharmaceutically acceptable vehicle.

Claims 6-20 (canceled)

Claim 21 (previously presented): A method of treating a microbial-related disease in a mammal comprising administering to the mammal a therapeutically effective amount of a polypeptide selected from the group consisting of:

- a) amino acid residue 1 to amino acid residue 65 of SEQ ID NO:2;
- b) amino acid residue 23 to amino acid residue 67 of SEQ ID NO:10;
- c) amino acid residue 1 to amino acid residue 67 of SEQ ID NO:10;
- d) amino acid residue 30 to amino acid residue 63 of SEQ ID NO:2;
- e) amino acid residue 31 to amino acid residue 63 of SEQ ID NO:2;
- f) amino acid residue 30 to amino acid residue 64 of SEQ ID NO:2;
- g) amino acid residue 31 to amino acid residue 64 of SEQ ID NO:2;
- h) amino acid residue 20 to amino acid residue 67 of SEQ ID NO:10 and
- i) amino acid residue 22 to amino acid residue 67 of SEQ ID NO:10; wherein said polypeptide ameliorates said disease.

Claim 22 (previously presented): The method of claim 21 wherein said microbial-related disease is associated with the eye.

Claim 23 (previously presented): The method of claim 22 wherein said microbial-related disease is conjunctivitis.

Claim 24 (previously presented): The method of claim 21 wherein said microbial-related disease is associated with the ear.

Amendment and Response

Applicants: Adler et al. Serial No.: 10/091,166 Filed: March 5, 2002

For: NOVEL BETA-DEFENSINS

Claim 25 (previously presented): A method of contraception in a mammal comprising administering to the mammal a therapeutically effective amount of a polypeptide selected from the group consisting of:

- a) amino acid residue 1 to amino acid residue 67 of SEQ ID NO:10;
- b) amino acid residue 21 to amino acid residue 67 of SEQ ID NO:10;
- c) amino acid residue 23 to amino acid residue 67 of SEQ ID NO:10;
- d) amino acid residue 30 to amino acid residue 63 of SEQ ID NO:2;
- e) amino acid residue 31 to amino acid residue 63 of SEQ ID NO:2;
- f) amino acid residue 30 to amino acid residue 64 of SEQ ID NO:2;
- g) amino acid residue 31 to amino acid residue 64 of SEQ ID NO:2;
- h) amino acid residue 20 to amino acid residue 67 of SEQ ID NO:10; and
- i) amino acid residue 22 to amino acid residue 67 of SEQ ID NO:10.

Claims 26-44 (canceled)

Claim 45 (previously presented): The isolated protein of claim 1 wherein the polypeptide comprises amino acid residues 21 to 67 of SEQ ID NO:10.

Claim 46 (previously presented): The isolated protein of claim 1 wherein the polypeptide comprises amino acid residues 1 to 67 of SEQ ID NO:10.

Claims 47-49 (canceled)

Claim 50 (previously presented): An isolated polypeptide comprising amino acid residues 23 to 67 of SEQ ID NO:10.